Physician profile

William Stephens

Internal Medicine · Jackson, MS

NPI 1528130655

$379.34

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$72.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $152.21 2019
Radius Health, INC. $68.52 2019-2024 Tymlos
Pfizer INC. $42.57 2019-2021
Novo Nordisk INC $30.37 2019-2020
Abbott Laboratories $17.42 2023 Proclaim
Lilly USA, LLC $16.06 2022
Amgen INC. $15.34 2019
Amarin Pharma, INC. $14.59 2019
Boehringer Ingelheim Pharmaceuticals, INC. $11.21 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $11.05 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

William Stephens

$379.34

in general payments reported 2019-2025

Years
2019-2024
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/114041/william-stephens

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.